ObvioHealth Announces Mobile Application to Transform Clinical Studies

ObvioHealth, a global medical technology company, announces the launch of its mobile application for site-less clinical studies—ClaimIt. ClaimIt removes barriers currently troubling the clinical research industry by improving convenience for study subjects, enhancing compliance, lowering drop-out rates and accelerating data capture – all of which help reduce exorbitant costs for study sponsors and create opportunities to leverage the data capture from connected devices for clinical evaluation.

“For decades, the clinical research industry has needed modernization and now there’s a better option,” said Bryan Silverman, CEO of ObvioHealth.  “Our mobile model transforms the industry by putting patients first. ClaimIt democratizes clinical studies by allowing study subjects to take part in important healthcare research from the comfort of their homes.”

ClaimIt maintains best-in-class clinical standards and compliance in studies ranging from pharmaceutical and nutrition, to observational and more. ObvioHealth’s clinical professionals and medical doctors monitor each study while study participants use the ClaimIt app on their smart phones or tablets, recording study specific information and allowing for real-time data collection.

Study protocols can be designed with smart devices, such as a Bluetooth blood pressure monitor, and the data from such devices immediately integrates with the ClaimIt app – providing real-world evidence. ClaimIt also offers real-time, 24/7 data monitoring, meaning adverse events are detected immediately. Healthcare professionals can video chat or text with participants at any time.

“ClaimIt opened the door to new possibilities for Danone,” said Damien Paineau, Gut and Digital Program Director at Danone Nutricia Research, one of the initial sponsors leveraging the ClaimIt app. “We’re able to conduct a study on babies in a more efficient and user-friendly way. With ClaimIt, we screened 252 mothers and invited 121 into the study in about two weeks, and the study is off to a great start.” He added, “The collaboration helps to accelerate our ambition to deliver precision nutrition in the first 1,000 days, leveraging digital technology as a key enabler.”

ObvioHealth is financially backed by TKS1, a venture capital collaboration between SPRIM, a life sciences consulting agency with deep experience as a clinical research organization and Tikehau Capital (TKO.FP), an alternative asset management and investment company.  In March, ObvioHealth received a Series A investment.

“ClaimIt will help advance the latest treatments in healthcare, which is why we invested so confidently in ObvioHealth,” said Bruno de Pampelonne, CEO of Tikehau IM. “We’re happy to see the technology come to fruition and believe its transformation of the industry is just getting started.”

Find more information on ClaimIt, visit ObvioHealth’s official site here.

About ObvioHealth
ObvioHealth is a full-service CRO that uses technology to drive clinical research in a cost-effective manner. As a medical technology company, ObvioHealth provides healthcare clients a data-rich platform for substantiating claims and demonstrating product safety and efficacy.

ObvioHealth has a proprietary application, ClaimIt, to conduct clinical trials online. This decentralized model means clinical trials can be executed from a participant’s smart phone, while leveraging the best-practices in study design, data management and medical writing–all in a streamlined platform. 

About SPRIM
SPRIM is a global life sciences innovation firm. With a team of 600+ professionals and 19 offices globally, SPRIM helps its clients transform the newest opportunities and breakthroughs in science and health, into business and marketing realities.  After 17 years in business, SPRIM offers its services to more than 450 customers around the globe.  Further information can be found at www.sprim.com.

About Tikehau Capital
Tikehau Capital is an asset management and investment group with €14.2 billion worth of assets under management and equity of €2.5 billion. The Group invests in various classes of assets (i.e., private debt, real-estate, private equity and liquid strategies), particularly through its asset management subsidiary Tikehau IM, on behalf of both institutional and private investors. Tikehau Capital is controlled by its managers and leading institutional partners and employs 220 people in its Paris, London, Brussels, Madrid, Milan, New York, Seoul and Singapore offices.

Tikehau Capital is listed on Euronext Paris, compartment A (ISIN code: FR0013230612; Ticker: TKO.FP). For more information, visit www.tikehaucapital.com.

About Danone Nutricia Research
Danone’s Nutricia Research is the global research and innovation organisation behind Danone Early Life Nutrition and Nutricia Advanced Medical Nutrition. We bring health through food to as many people as possible, particularly those who need special care. Science is at the heart of our nutrition and health commitment. Thus we focus our skills and resources to deliver evidence-based specialized nutrition to infants, young children, patients and the elderly. This helps individuals build, to establish and to preserve their health capital during early life or later in life.

By bringing employees from different backgrounds and with complementary scientific expertise together, we create a creative, high team-spirit powerhouse to deliver new innovations in specialized nutrition.

We work in strategic partnerships including research institutes, universities, hospitals and industrial suppliers. By operating in a strong worldwide network of collaboration, innovation through quality, exclusivity and momentum can be guaranteed.

For more info: www.nutriciaresearch.com

About Danone
Dedicated to bringing health through food to as many people as possible, Danone is a leading global food & beverage company built on four businesses: Essential Dairy and Plant-Based Products, Waters, Early Life Nutrition and Advanced Medical Nutrition. Danone aims to inspire healthier and more sustainable eating and drinking practices, in line with its vision -Danone, One Planet. One Health- which reflects a strong belief that the health of people and the health of the planet are interconnected. Building on health-focused categories, Danone commits to operating in an efficient and responsible manner to create and share sustainable value.  Danone holds itself to the highest standards in doing business, as reflected by its ambition to become one of the first multinationals certified as B Corp. With products sold in over 120 markets, Danone generated sales of €24.7 billion in 2017. Danone’s portfolio includes leading international brands (Activia, Actimel, Alpro, Aptamil, Danette, Danio, Danonino, evian, Nutricia, Nutrilon, Volvic, amongst others) as well as strong local and regional brands (including AQUA, Blédina, Bonafont, Cow & Gate, Horizon Organic, Mizone, Oikos, Prostokvashino, Silk and Vega).

Listed on Euronext Paris and on the OTCQX market via an ADR (American Depositary Receipt) program, Danone is a component stock of leading social responsibility indexes including the Dow Jones Sustainability Indexes, Vigeo, the Ethibel Sustainability Index, MSCI Global Sustainability, MSCI Global SRI Indexes and the FTSE4Good Index.

For more info: https://www.danone.com/

Contact Information

Meghan Witthaus

Assistant Account Executive

Racepoint Global

Contact via E-mail